Ironwood Pharmaceuticals, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report, not a standalone fourth-quarter filing; it also reports unaudited quarterly results. Ironwood is a commercial biotechnology company whose revenue depends primarily on its U.S. LINZESS collaboration with Allergan. The company launched ZURAMPIC in the U.S. in October 2016 after licensing U.S. lesinurad rights from AstraZeneca.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Collaborative arrangements revenue | $274.0 million | $149.6 million |
| Operating loss | $51.9 million | $102.1 million |
| Net loss | $81.7 million | $142.7 million |
| Net loss per share, basic and diluted | $0.56 | $1.00 |
| Research and development expense | $139.5 million | $108.7 million |
| Selling, general and administrative expense | $173.3 million | $125.2 million |
| Net cash used in operating activities | $25.4 million | $106.9 million |
| Cash, cash equivalents and available-for-sale securities, year-end | $305.2 million | $439.4 million |
Revenue increased 83%, led by an $84.3 million increase in Ironwood’s share of U.S. LINZESS net profits and $30.0 million in Astellas milestones for Japanese filing and approval. LINZESS-related revenue from Allergan’s North America collaboration was $223.4 million, including $217.7 million from U.S. collaboration profit-sharing. Reported ZURAMPIC sales revenue was insignificant in 2016; under the company’s sell-through approach, revenue was recognized when prescriptions reached end users.
Operating expenses totaled $325.8 million, up 29%. The net loss narrowed by $61.0 million year over year, despite higher R&D and commercial spending, as revenue growth and a smaller inventory write-down offset those increases. Operating cash use improved, but the company remained loss-making and was not cash-flow positive. Cash and securities declined by $134.2 million during the year, principally reflecting the $100.0 million lesinurad license payment and operating needs. The filing says year-end cash was expected to fund projected operating needs for at least 12 months.
Year-end total indebtedness was reported at approximately $470 million; the balance sheet carried debt financing and convertible notes at $366.5 million, net of discounts and issuance costs. This included the 2.25% convertible notes due 2022 and PhaRMA notes, which were redeemed on January 5, 2017 using proceeds from $150.0 million of 8.375% notes due 2026. The 2026 notes require payments linked to U.S. LINZESS sales, subject to minimum interest provisions. No operating margin or conventional product gross margin is clearly stated in the filing.
For the fourth quarter of 2016, revenue was $87.5 million and net loss was $13.5 million, compared with $53.3 million and $14.0 million, respectively, in fourth-quarter 2015.
Material changes and business developments
- Ironwood paid AstraZeneca $100.0 million for exclusive U.S. lesinurad rights. ZURAMPIC launched in October; the company was building its own commercial capabilities while relying on AstraZeneca for supply and transition services.
- R&D expense increased 28%, including greater lesinurad and early-pipeline investment. SG&A increased 38%, largely due to ZURAMPIC launch staffing, sales, marketing and infrastructure.
- LINZESS revenue growth remained the principal driver of results. The Allergan U.S. collaboration shares net profits or losses equally, subject to contractual sales-call adjustments.
- In December, Ironwood and Allergan reported positive top-line Phase IIb results for linaclotide colonic-release candidates CR1 and CR2. Management said CR1 data supported Phase III advancement; CR2 warranted further study.
- Japan approved LINZESS for adult IBS-C in December 2016. In January 2017, the FDA approved a 72 mcg LINZESS dose for adults with CIC and accepted DUZALLO for review.
- Ironwood discontinued IW-9179 after studies did not show meaningful symptom reduction for diabetic gastroparesis; it also stopped advancing the program for functional dyspepsia.
Outlook, risks and unusual items
Management expects substantial R&D and commercialization spending to continue and identifies becoming cash-flow positive as a goal, not a forecast or guarantee. The filing provides no quantified revenue or earnings guidance. The company states it cannot predict when, or whether, it will become profitable or cash-flow positive.
- Revenue concentration: Substantially all revenue came from the LINZESS collaboration, principally Allergan in the U.S.; revenue can vary with product demand, collaboration costs, milestones and partner reporting.
- Debt and liquidity: Debt service and the LINZESS-linked 2026 note payments create obligations tied to collaboration cash flows. The company may need additional financing, which may not be available on acceptable terms.
- Safety and regulatory obligations: LINZESS carries a pediatric boxed warning. ZURAMPIC carries a boxed warning concerning acute renal failure, particularly if used without an XOI, and requires a post-marketing renal and cardiovascular safety study. Ironwood may reimburse AstraZeneca up to $100 million over as many as ten years for required ZURAMPIC post-marketing activities.
- Generic litigation: Ironwood and Allergan sued four generic applicants over LINZESS patents in November 2016. The lawsuits triggered an FDA approval stay through February 29, 2020, absent an earlier adverse decision or court adjustment. Outcomes remain uncertain.
- Supply and partner dependence: Ironwood has no internal manufacturing or distribution capability and relies on third parties for linaclotide and exclusively on AstraZeneca for lesinurad finished product. Supply interruption or partner performance problems could impair commercialization.
- Competition and reimbursement: Generic and OTC constipation therapies, branded competitors, payer restrictions and pricing pressure may limit adoption or margins.
- Notable accounting items: 2016 included a $9.8 million fair-value loss on lesinurad contingent consideration and an $8.1 million derivative gain. The lesinurad acquisition’s preliminary purchase-price allocation was revised during the year; final valuation remained subject to further adjustment.
Ernst & Young issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective at year-end.
Key facts for investors to verify
- Trends in U.S. LINZESS net sales, collaboration expenses and the resulting cash payments from Allergan.
- ZURAMPIC prescription uptake, reimbursement, sell-through revenue recognition and the costs of its commercial launch.
- DUZALLO’s FDA review outcome and the final lesinurad acquisition valuation, contingent payments and royalties.
- Progress, cost and results of required ZURAMPIC safety studies and LINZESS pediatric studies.
- Status and outcomes of the LINZESS generic patent litigation and any patent challenges.
- Cash runway, debt service and the terms and cash-flow effects of the 2026 notes and remaining 2022 convertible notes.